CD205

Synonyms

LY75, CD205, Lymphocyte Antigen 75, C-Type Lectin Domain Family 13 Member B, CLEC13B, DEC-205, CD205 Antigen, Gp200-MR6, Ly-75,

Description

Lymphocyte antigen 75 also called CD205 is a protein that in humans is encoded by the LY75 gene. Lymphocyte antigen 75 acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen-processing compartment.

KO Status

Drug Information

Launched drugs: 0
Drugs in clinical trials: 2
Latest Research Phase:Phase 2 Clinical

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Rasdegafusp alfa

CDX-1401

Phase 2 Clinical

Ludwig Institute For Cancer Research

Ovarian Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Breast Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Carcinoma, Non-Small-Cell Lung

NCT Number

NCT02129075

NCT02495636

NCT00948961

NCT03206047

NCT02166905

NCT02413827

NCT02661100

NCT01834248

NCT01522820

Intervention Type

Other;Biological

Drug

Biological

Other;Biological;Drug

Drug

Biological;Drug

Other;Biological;Drug

Indications

Cutaneous Melanoma; Mucosal Melanoma; Ocular Melanoma; Stage IIB Cutaneous Melanoma AJCC v6 and v7; Stage IIC Cutaneous Melanoma AJCC v6 and v7; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7

Non-Small Cell Lung Cancer

Advanced Malignancies

Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma

Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma

Unresectable Stage III or Stage IV Melanoma

Non Small Cell Lung Cancer; Advanced Triple Negative Breast Cancer; Small Cell Lung Cancer; Urothelial Cancer; Mesothelioma; Malignant Melanoma

Acute Myeloid Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation

Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Anaplastic Oligodendroglioma; Estrogen Receptor Negative; Estrogen Receptor Positive; Glioblastoma; Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Metastatic Renal Cell Cancer; Recurrent Adult Brain Neoplasm; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Lung Carcinoma; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Uterine Corpus Carcinoma; Resectable Hepatocellular Carcinoma; Sarcoma; Stage IA Breast Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Corpus Cancer; Stage IB Breast Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Corpus Cancer; Stage IC Ovarian Cancer; Stage II Uterine Corpus Cancer; Stage IIA Breast Cancer; Stage IIA Lung Carcinoma; Stage IIA Ovarian Cancer; Stage IIB Breast Cancer; Stage IIB Esophageal Cancer; Stage IIB Lung Carcinoma; Stage IIB Ovarian Cancer; Stage IIB Skin Melanoma; Stage IIC Ovarian Cancer; Stage IIC Skin Melanoma; Stage IIIA Breast Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Lung Carcinoma; Stage IIIA Ovarian Cancer; Stage IIIA Skin Melanoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Breast Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Skin Melanoma; Stage IIIB Uterine Corpus Cancer; Stage IIIC Breast Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Skin Melanoma; Stage IIIC Uterine Corpus Cancer; Stage IV Bladder Urothelial Carcinoma; Stage IV Esophageal Cancer; Stage IV Ovarian Cancer; Stage IV Prostate Cancer; Stage IV Skin Melanoma; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer

Study Phase

Phase 2

Phase 1/Phase 2

Phase 1

Recruitment Status

Active, not recruiting

Withdrawn

Completed

Active, not recruiting

Terminated

Withdrawn

Completed

MEN-1309

MEN-1309, OBT-076

Phase 1 Clinical

Oxford Biotherapeutics, Menarini

Solid tumours, Breast Neoplasms, Lymphoma, Non-Hodgkin